1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
OliX Pharmaceuticals, Inc.

OliX Pharmaceuticals, Inc.

KKRX:226950
103,300.00
KRW
-2,300.00
(-2.18%)
-662.61EPS
3.16TMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
262.38
159.67
45.03
26.27
26.04
86.8
188.13
268.08
680.31
1,182.78
337.07
745.33
643.99
Basic EPS, GAAP
-69
-524.5
-420
-556
-667.5
-1,102.23
-1,473.86
-2,168
-1,423
-1,324
-2,414
-800
-662.61
Free Cash Flow per Basic Share
471.57
-805.78
-772.19
-659.04
-850.71
-907.03
-374.14
-3,307.94
-2,424.6
-2,095.8
-2,501.04
-902.37
-1,526.12
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
80.32
680.82
1,206.15
1,793.9
4,223.45
3,200.42
3,344.07
1,351.59
4,700.19
3,084.79
966.92
7,309.62
11,609.97
Tangible Book Value per Share
76.45
658.04
1,184.24
1,765.25
4,120.51
3,092.41
3,157.3
1,195.84
4,546.39
2,961.16
874.55
7,213.84
11,511.96
Basic Weighted Avg Shares
2
6
9
9
12
13
13
14
14
14
17
20
21
Sales/Revenue/Turnover
646
908
392
244
302
1,130
2,474
3,674
9,320
17,064
5,677
14,667
13,636
Operating Margin (%)
14.83
-239.91
-975.19
-2,217.53
-2,726.47
-1,337.38
-656.41
-659.4
-240.07
-106.57
-544.61
-204.35
-304.72
Depreciation Expense
16
55
137
370
508
776
1,141
1,630
2,075
2,642
2,626
2,454
2,345
Net Income, GAAP
-170
-2,982
-3,656
-5,164
-7,742
-14,353
-19,385
-29,715
-19,495
-19,102
-40,659
-15,743
-14,030
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-26.3
-328.5
-932.79
-2,116.66
-2,563.58
-1,269.79
-783.44
-808.7
-209.17
-111.94
-716.18
-107.33
-102.89
Working Capital
623
5,977
9,253
15,142
48,384
34,685
64,559
11,874
25,502
25,578
-14,526
119,525
200,871
LT Debt
407
715
1,400
1,400
- -
207
14,268
20,052
23,826
38,292
21,434
18,753
16,807
Total Equity
836
7,088
12,557
18,676
54,938
41,807
45,351
19,407
66,203
50,336
18,473
150,079
237,420
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-75.25
-37.22
-33.07
-21.03
-29.67
-44.52
-93.14
-47.02
-33.56
-120.89
-18.94
-10.86

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,534
3,995
4,013
LT Borrowings
17,857
16,964
16,071
LT Finance Leases
896
834
735
Preferred Equity and Hybrid Capital
990
990
990
Shares Outstanding
20
20
20
Market Capitalization
2,850,202
3,757,638
3,158,771

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
140,851
132,179
219,578
Cash, Cash Equivalents & STI
132,513
108,394
214,149
Accounts Receivable, Net
5,127
- -
- -
Inventories
397
418
426
Total Current Liabilities
21,326
20,046
18,708
Payables & Accruals
- -
- -
- -
ST Debt
4,534
3,995
4,013
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
111.37%
161.82%
712.44%
Free Cash Flow
82.75%
153.43%
-57.85%
Net Income, GAAP
30.27%
13.69%
-61.28%
Sales/Revenue/Turnover
69.93%
75.37%
158.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
768
4,600
264
45
5,677
2025
977
6,251
2,909
4,531
14,667
2026
3,572
2,625
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-512
-578
-621
-701.81
-2,414
2025
-709
-465
-433.03
762.35
-800
2026
-439.87
-493
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dong-Gi Lee
Full Time Employees
76
Sector
Health technology
Industry
Pharmaceuticals: major
Address
#1014 Gwanggyo Ace Tower1, 17 Seongnam-si GY South Korea 16226
IPO Date
Jul 18, 2018
Website
olixpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
OliX Pharmaceuticals, Inc. operates as a clinical-stage biotechnology firm, dedicated to advancing RNA interference (RNAi) based therapies for a range of medical conditions. The company leverages its proprietary asymmetric siRNA (asiRNA) and cell-penetrating asymmetric siRNA (cp-asiRNA) platforms, designed to enhance gene silencing with reduced off-target effects and improved cellular delivery. Its diverse investigational portfolio includes compounds addressing various therapeutic areas. Within the dermal segment, lead candidates include OLX101A for hypertrophic scarring, which completed Phase 2a enrollment in the U.S. and has been licensed for development, alongside OLX104C targeting androgenic alopecia. The ophthalmic pipeline features OLX301A for dry and wet age-related macular degeneration (AMD), currently in Phase 1 trials in the U.S., and OLX10212, which received U.S. FDA IND approval for Phase 1 studies in AMD. OLX304A is also under development for retinitis pigmentosa. For pulmonary diseases, compounds like OLX201 are being developed for lung fibrosis. Expanding into systemic treatments, OliX utilizes its GalNAc-asiRNA technology for liver-focused therapies, including OLX75016 for metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications, a program that secured a significant global licensing agreement with Eli Lilly and Company in February 2025. OLX702A for NASH and OLX703A for hepatitis B virus are also in preclinical development. The company has also initiated collaborations for RNA-based antibody-drug conjugate (ADC) therapeutics and entered an exclusive scientific partnership with L'Oréal Groupe for beauty innovation in skin and hair regeneration. Established in 2010, OliX Pharmaceuticals, Inc. is headquartered in Seongnam, South Korea.